Lung Cancer Trial, Recruiting (NCT05306912)

Lung Cancer Trial, Recruiting NCT05306912 Sponsor: University Hospital, Toulouse Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05306912 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

A bronchoscopy procedure using a specific ultrasound-guided technique (called rEBUS) is planned to examine one, two, or three small spots in the lung, each no larger than 20mm
The person's general health and ability to carry out daily activities falls within an acceptable range, as rated by a standard medical scale (WHO Performance Status 0–3)
The person has given their signed agreement to take part in the trial
The person is covered by a qualifying French social security or health insurance scheme

Who may not be able to join:

Lung cancer has already been diagnosed before the date of the planned procedure
Lung cancer is strongly suspected based on signs found in the area between the lungs or outside the chest
The person is receiving healthcare coverage through State Medical Assistance (Aide Médicale de l'État) in France
The person is currently detained, or is under a legal protection measure such as guardianship, curatorship, or court-ordered safeguarding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Valentin HELUAIN, MD, University Hospital, Toulouse

Phone: +33567771439

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05306912

Sponsor: University Hospital, Toulouse

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: +33567771439

More information: https://clinicaltrials.gov/study/NCT05306912

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

A bronchoscopy procedure using a specific ultrasound-guided technique (called rEBUS) is planned to examine one, two, or three small spots in the lung, each no larger than 20mm
The person's general health and ability to carry out daily activities falls within an acceptable range, as rated by a standard medical scale (WHO Performance Status 0–3)
The person has given their signed agreement to take part in the trial
The person is covered by a qualifying French social security or health insurance scheme

Who may not be able to join:

Lung cancer has already been diagnosed before the date of the planned procedure
Lung cancer is strongly suspected based on signs found in the area between the lungs or outside the chest
The person is receiving healthcare coverage through State Medical Assistance (Aide Médicale de l'État) in France
The person is currently detained, or is under a legal protection measure such as guardianship, curatorship, or court-ordered safeguarding

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital, Toulouse

Registry

ClinicalTrials.gov

Start date

8 April 2022

Est. completion

1 December 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Sensitivity of targeted (9 genes panel) methylation analysis on supernatant cfDNA to detect a malignant nodule will be evaluated.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov